Infl uence of GSTM1 and NAT2 deletion polymorphism on effi ciency of TB reatment and selection of way of addministration of anti-TB reparations

Todoriko, Lilia; Antonenko, P. B.; Kuzhko, M. М.; Semianiv, Ihor; Tlustova, T. V.

doi:10.32902/2663-0338-2019-19-1-9-16

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as cytochrome-4502E1 (CYP2E1), N-acetyltransferase 2, and glutathione S-transferase [6,7]. In addition, the abovementioned enzymes play an important role in biotransformation of the anti-TB drugs.…”

Section: клінічна практикаmentioning

confidence: 99%

Prognostic Value of Cyp3a4*1b Polymorphism in Patients With Pulmonary Tuberculosis

Poludenko,

Antonenko,

Antonenko

et al. 2024

The Odesa Medical Journal

View full text Add to dashboard Cite

Introduction. Previously it was found that in slow metabolizers according to CYP3A4*1G genotype after completion of in-patient stage of anti-tuberculosis treatment, the level of cytolysis and toxicity indexes was much higher than in rapid metabolizers. The aim of the present research was to find the meaning of CYP3A4*1В polymorphism in tuberculosis (TB) patients for the level of isoniazid and rifampicin as well as for the outcome and toxicity development during in-patient TB treatment.Materials and methods. The medical records of 105 patients with pulmonary tuberculosis were examined. All these patients had primary pulmonary tuberculosis. They were receiving in-patient treatment at the Odesa Regional Center for Socially Significant Diseases (previouslythe Odesa Regional Tuberculosis Dispensary) in 2012-2014. The study was conducted under the Declaration of Helsinki standards.Results. After in-patient treatment, the activity of cytolysis markers as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and the cholestasis marker as gamma-glutathione transferase (GGT) in TB-patients with *AA genotype increased insignificantly by 7.0%, 9.3%, and 4.5% (p>0.05); in patients with the *AG genotype, the activity of ALT, AST and GGT, on the contrary, had a tendency for decreasing -by 18.7%, 3.0% and 9.0% (p>0.05); a similar trend was observed concerning the number of patients with increased activity of ALT, AST and GGT. At the end of treatment, the average activity of ALT in carriers of the *AA genotype was 1.8 times higher than in carriers of the *AG genotype (p=0.046; . Conclusion.At the beginning of anti-tuberculosis chemotherapy, it is recommended to determine the CYP3A4*1B genotype in patients with pulmonary tuberculosis, which allow identifying the groups of patients with the *AG genotype, which is characterized by a greater risk of developing sub-therapeutic rifampicin concentrations in the blood during treatment and prove the usefulness of personalized choice of rifampicin dosage according to the CYP3A4*1B genotype.

show abstract

Section: клінічна практикаmentioning

confidence: 99%